A distressed micro-cap with a newly reclaimed U.S. PDT franchise: survive the liquidity clock, win sBCC approval, and the valuation could re-rate dramatically.
Overview
Biofrontera Inc. (BFRI) is a specialized U.S. dermatology biopharma at an inflection point in late 2025, transitioning from a constrained U.S. commercial arm of Biofrontera AG into a more independent, IP-owning operator. Its core asset is Ameluz (ALA 10% gel) used with the BF‑RhodoLED lamp for FDA-approved lesion- and field-directed treatment of mild-to-moderate actinic keratoses on the face/scalp. A major 2025 restructuring reshaped the economics: BFRI acquired the U.S. NDA/PMA and related patents/trademarks for Ameluz/RhodoLED and reduced royalties from a tiered structure peaking around 35% to a fixed 12–15% of net sales, creating a contractual path to improved gross margins and a targeted 2026 breakeven. The near-term clinical catalyst is the Nov 28, 2025 sNDA seeking approval for Ameluz in superficial basal cell carcinoma (sBCC); approval would make it the only PDT drug explicitly labeled for sBCC in the U.S. and expand the addressable market from pre-cancer into true oncology. The company also sold its Xepi license to Pelthos for up to $10M (including $3M upfront), focusing resources on PDT and adding non-dilutive liquidity. Despite these positives, BFRI remains a distressed micro-cap with ongoing losses, a short cash runway, convertible-debt dilution risk, and Nasdaq bid-price compliance pressure (sub-$1 stock), making the equity a binary “special situation” rather than a conventional compounder.